Liver resection for colorectal cancer metastases

Current Oncology

Volumn 20, Issue 3, 2013, Pages

  Gallinger, S ^a   Biagi, J J ^b   Fletcher, G G ^c   Nhan, C ^d   Ruo, L ^e   McLeod, R S ^f  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CANCER CARE ONTARIO   (Canada)

^e MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chemotherapy; Colorectal cancer metastases; Complete response; Downstaging; Hepatic resection; Liver resection

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; EVIDENCE BASED PRACTICE; EXTRAHEPATIC METASTASIS; HUMAN; LIVER RESECTION; LUNG METASTASIS; LUNG RESECTION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT DECISION MAKING; PEER REVIEW; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SYSTEMIC THERAPY; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 84878754475     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1341     Document Type: Article

References (58)

1. Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 2011;103:21-30.
2. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008;26:5721-7.
3. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6.
4. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77:1241-6.
5. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:1405-10.
6. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by folfox6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
7. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
8. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-25.
9. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in longterm survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759-66.
10. Jonas S, Thelen A, Benckert C, et al. Extended resections of liver metastases from colorectal cancer. World J Surg 2007;31:511-21.
11. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 1996;77:1254-62.
12. Shah SA, Bromberg R, Coates A, Rempel E, Simunovic M, Gallinger S. Survival after liver resection for metastatic colorectal carcinoma in a large population. J Am Coll Surg 2007;205:676-83.
13. Wright F, De Vito C, Langer B, Hunter A On behalf of the Expert Panel on Multidisciplinary Cancer Conference Standards. Special Report: Multidisciplinary Cancer Conference Standards. Toronto, ON: Cancer Care Ontario; 2006. [Available online at: http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=14318; cited June 28, 2012]
14. Wright FC, De Vito C, Langer B, Hunter A on behalf of the Expert Panel on Multidisciplinary Cancer Conference Standards. Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer 2007;43:1002-10.
15. Marcaccio M, Langer B, Rumble B, Hunter A On behalf of the Expert Panel on HPB Surgical Oncology. Hepatic, Pancreatic, and Biliary Tract (HPB) Surgical Oncology Standards. Evidence-based series special report no. 17-2. Toronto, ON: Cancer Care Ontario; 2006. [Available online at: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=139394; cited June 28, 2012]
16. Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin North Am 2002;82:1075-90.
17. Van Cutsem E, Nordlinger B, Cervantes A, on behalf of the ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010;21(suppl 5):v93-7.
18. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715-22.
19. Van Cutsem E, Nordlinger B, Adam R, et al. on behalf of the European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006;42:2212-21.
20. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:1261-8.
21. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002;137:675-80.
22. Azoulay D, Castaing D, Smail A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 2000;231:480-6.
23. Shoup M, Gonen M, D'Angelica M, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003;7:325-30.
24. Vauthey JN, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 2004;239:722-30.
25. Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012;255:405-14.
26. Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009;19:1206-13.
27. McKay A, Fradette K, Lipschitz J. Long-term outcomes following hepatic resection and radiofrequency ablation of colorectal liver metastases. HPB Surg 2009;2009:346863.
28. Stang A, Fischbach R, Teichmann W, Bokemeyer C, Braumann D. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009;45:1748-56.
29. Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010;28:493-508.
30. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-12.
31. Browman GP, Newman TE, Mohide EA, et al. Progress of clinical oncology guidelines development using the practice guidelines development cycle: the role of practitioner feedback. J Clin Oncol 1998;16:1226-31.
32. Quan D, Gallinger S, Nhan C, et al. on behalf of the Surgical Oncology Program at Cancer Care Ontario. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery 2012;151:860-70.
33. Gallinger S, Biagi JJ, Fletcher GG, et al. The Role of Liver Resection in Colorectal Cancer Metastases. Evidence-based series no. 17-7. Toronto, ON: Cancer Care Ontario; 2012. [Available online at: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=154968; cited June 27, 2012]
34. Shah SA, Haddad R, Al-Sukhni W, et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006;202:468-75.
35. Jaeck D, Nakano H, Bachellier P, et al. Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol 2002;9:430-8.
36. Adam R, de Haas RJ, Wicherts DA, et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol 2008;26:3672-80.
37. Oussoultzoglou E, Romain B, Panaro F, et al. Long-term survival after liver resection for colorectal liver metastases in patients with hepatic pedicle lymph nodes involvement in the era of new chemotherapy regimens. Ann Surg 2009;249:879-86.
38. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-57.
39. Gallagher DJ, Zheng J, Capanu M, et al. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol 2009;16:1844-51.
40. Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 2003;90:567-74.
41. Carpizo DR, Are C, Jarnagin W, et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol 2009;16:2138-46.
42. Elias D, Sideris L, Pocard M, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004;11:274-80.
43. Elias D, Liberale G, Vernerey D, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005;12:900-9.
44. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:1271-80.
45. Nordlinger B, Sorbye H, Glimelius B, et al. on behalf of the EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with folfox4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16.
46. Mitry E, Fields ALA, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26:4906-11.
47. Nordlinger B, Van Cutsem E, Gruenberger T, et al. on behalf of the European Colorectal Metastases Treatment Group and the Sixth International Colorectal Liver Metastases Workshop. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009;20:985-92.
48. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Ver. 2.2011. Fort Washington, PA: NCCN; 2011. [Available online at: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf; cited January 25, 2011]
49. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Ver. 2.2011. Fort Washington, PA: NCCN; 2011. [Available online at: http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf; cited January 25, 2011]
50. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872-7.
51. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006;243:1-7.
52. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009;249:420-5.
53. Nuzzo G, Giuliante F, Ardito F, et al. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 2007;11:318-24.
54. Skof E, Rebersek M, Hlebanja Z, Ocvirk J. Capecitabine plus irinotecan (XELIRI regimen) compared to 5-FU/LV plus irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer 2009;9:120.
55. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939-45.
56. Fiorentini G, Del Conte A, De Simone M, et al. Complete response of colorectal liver metastases after intra-arterial chemotherapy. Tumori 2008;94:489-92.
57. Tanaka K, Takakura H, Takeda K, Matsuo K, Nagano Y, Endo I. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg 2009;250:935-42.
58. Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy- missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007;14:3188-94.